In the last trading session, 2.15 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 1.76. With the company’s per share price at $44.51 changed hands at -$2.06 or -4.42% during last session, the market valuation stood at $3.82B. CRSP’s last price was a discount, traded about -103.59% off its 52-week high of $90.62. The share price had its 52-week low at $36.52, which suggests the last value was 17.95% up since then.
Analysts gave the CRISPR Therapeutics AG (CRSP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.97. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CRSP as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. CRISPR Therapeutics AG’s EPS for the current quarter is expected to be -1.28.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Instantly CRSP was in red as seen at the end of in last trading. With action -14.76%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 13.08%, with the 5-day performance at -14.76% in the red. However, in the 30-day time frame, CRISPR Therapeutics AG (NASDAQ:CRSP) is 2.51% up.
The consensus price target for the stock as assigned by Wall Street analysts is 67, meaning bulls need an upside of 33.57% from its current market value. According to analyst projections, CRSP’s forecast low is 65 with 95 as the target high. To hit the forecast high, the stock’s price needs a -113.44% plunge from its current level, while the stock would need to soar -46.03% for it to hit the projected low.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Year-over-year growth is forecast to reach 59.92% up from the last financial year.
Consensus estimates given by 15 financial analysts project the company’s revenue in the current quarter to hit an average of 6.68M. 15 analysts are of the opinion that CRISPR Therapeutics AG’s revenue for the current quarter will be 9.77M. The company’s revenue for the corresponding quarters a year ago was 504k and 517k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1,225.01%. The estimates for the next quarter sales put growth at 1,790.54%.
The 2025 estimates are for CRISPR Therapeutics AG earnings to decrease by -9.69%, but the outlook for the next 5-year period is at 24.15% per year.
CRSP Dividends
CRISPR Therapeutics AG is expected to release its next quarterly earnings report in March.
ARK INVESTMENT MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 9.1597% or 7.78 million shares worth $420.12 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc . With 6.44 shares estimated at $286.51 million under it, the former controlled 7.50% of total outstanding shares. On the other hand, New Perspective Fund Inc held about 5.59% of the shares, roughly 4.79 shares worth around $213.26 million.
